Topics:

Phase I Trial of an Oral/Oral Combination Accruing Patients

Phase I Trial of an Oral/Oral Combination Accruing Patients

MARTINSREID/MUNICH, Germany—GPC Biotech AC is accruing patients with advanced solid tumors onto a phase I trial of satraplatin, its investigational oral platinum agent, in combination with capecitabine (Xeloda). The open label study of the oral/oral combination, led by William Gradishar, MD, of Northwestern University, is expected to enroll approximately 24 patients, the company indicated in a news release.

 
Loading comments...
Please Wait 20 seconds or click here to close